The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Impax Laboratories's revenues will shrink -20.2% and EPS will contract -50.0%.
The average estimate for revenue is $126.6 million. On the bottom line, the average EPS estimate is $0.18.
Last quarter, Impax Laboratories logged revenue of $145.6 million. GAAP reported sales were 21% higher than the prior-year quarter's $119.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.48. GAAP EPS of $0.29 for Q3 were 12% higher than the prior-year quarter's $0.26 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 53.6%, 130 basis points better than the prior-year quarter. Operating margin was 20.0%, 290 basis points worse than the prior-year quarter. Net margin was 13.8%, 60 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $575.2 million. The average EPS estimate is $1.76.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 170 members out of 183 rating the stock outperform, and 13 members rating it underperform. Among 58 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 55 give Impax Laboratories a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Impax Laboratories is outperform, with an average price target of $25.59.
- Add Impax Laboratories to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Impax Laboratories Inc Is Tanking Today
Traders flee after the company announces that it is merging with a privately held drugmaker.
Why Calgon Carbon, Kindred Healthcare, and Impax Laboratories Jumped Today
These stocks defied a downward-moving market. Find out why.
Why Impax Laboratories Inc Is Up for a Second Straight Day
Analysts upped their price targets following a solid second-quarter report from the drugmaker.